F. Cardenal

发表

Low ERCC 1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer 1

D. Gandara, R. Rosell, K. Danenberg, 2002 .

Brain functional connectivity in lung cancer population: an exploratory study

Antoni Rodríguez-Fornells, A. Rodríguez-Fornells, P. Ripollés, 2018, Brain Imaging and Behavior.

Cognitive and Brain Structural Changes in a Lung Cancer Population

Antoni Rodríguez-Fornells, Pablo Ripollés, Lucía Vaquero, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brain damage following prophylactic cranial irradiation in lung cancer survivors

Antoni Rodríguez-Fornells, Pablo Ripollés, Lucía Vaquero, 2015, Brain Imaging and Behavior.

Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.

N. Malats, F. Real, N. Viñolas, 1997, Journal of the National Cancer Institute.

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

J. Soria, A. Szczesna, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

M. Taron, S. Benlloch, T. Moran, 2010 .

High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC

S. Novello, L. Paz-Ares, C. Langer, 2008 .

Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer

Antoni Rodríguez-Fornells, Pablo Ripollés, Lucía Vaquero, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer

J. Debus, G. Scagliotti, R. Ramlau, 2006, British Journal of Cancer.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

E. Felip, R. Rosell, M. Taron, 2012 .

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Rosell, M. Taron, M. Provencio, 2008 .

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

C. García-Girón, R. Rosell, M. Taron, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

A. Bezjak, J. V. van Meerbeeck, C. Faivre-Finn, 2017, The Lancet. Oncology.

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

L. Paz-Ares, C. Langer, L. Terstappen, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

R. Rosell, M. Sánchez-Ronco, B. Massuti, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Opioids for the Management of Dyspnea in Cancer Patients: Evidence of the Last 15 Years—A Systematic Review

J. Porta-Sales, F. Cardenal, Alejandro Vargas-Bermúdez, 2015, Journal of pain & palliative care pharmacotherapy.

Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancer.

J. Bruna, E. Nadal, F. Cardenal, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized P hase I II S tudy o f G emcitabine-Cisp latin Versus E toposide-Cispla tin i n t he T reatment o f L ocally Advanced o r M etastatic N on-Small-Cell L ung C ancer

A. Carrato, R. Rosell, B. Massuti, 1999 .

Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer.

S. Novello, M. Dolled-Filhart, L. Paz-Ares, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Typhlitis associated with docetaxel treatment.

G. Llort, R. Mesía, F. Cardenal, 1996, Journal of the National Cancer Institute.

Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.

J. von Pawel, U. Gatzemeier, N. Samaras, 2000, American journal of clinical oncology.

Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy.

R. Mesía, M. Majem, F. Cardenal, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Does Induction Chemotherapy Still Have a Role in Larynx Preservation Strategies? The Experience of Institut Catala d'Oncologia in Stage III Larynx Carcinoma

R. Mesía, M. Majem, F. Cardenal, 2006, The Laryngoscope.

Etoposide-related acral erythema

F. Cardenal, X. Garcia-Del-Muro, I. Portal, 2004, Cancer Chemotherapy and Pharmacology.

A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.

R. Salazar, M. Izquierdo, R. Mesía, 2006, European journal of cancer.

CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016 .

Brain damage following prophylactic cranial irradiation in lung cancer survivors

A. Rodríguez-Fornells, P. Ripollés, M. Simó, 2016, Brain Imaging and Behavior.

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and goo

A. Bezjak, C. Faivre-Finn, P. Lorigan, 2016, BMJ Open.

Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer.

A. Urruticoechea, R. Mesía, M. Majem, 2004, Lung cancer.

Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

D. Beer, Lin Lin, Guoan Chen, 2013, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis Epigenetic Inactivation of microRNA-34 b / c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

D. Beer, Lin Lin, Guoan Chen, 2013 .

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

N. Malats, F. Real, W. Mason, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial.

E. Felip, J. Astudillo, P. Garrido, 2000, Clinical lung cancer.

Screening for epidermal growth factor receptor mutations in lung cancer.

Mariano Provencio, Miguel Angel Molina, Bartomeu Massuti, 2009, The New England journal of medicine.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

J. Mate, C. Sawyers, A. Ariza, 2011, Clinical Cancer Research.

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

K. Nackaerts, U. Dafni, K. Syrigos, 2022, Modern Pathology.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

D. Gandara, R. Rosell, K. Danenberg, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

D. Beer, Guoan Chen, A. Chang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

A. Carrato, R. Rosell, B. Massuti, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature.

C. Faivre-Finn, E. Nadal, M. Jové, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Cancer OncoGuia

J. Lloreta, M. Alejo, E. Felip, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

B. Massuti, M. Provencio, C. Camps, 2012, Cancer Chemotherapy and Pharmacology.

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

E. Felip, R. Rosell, N. Viñolas, 2011, Lung cancer.

Extrapyramidal reaction associated with ondansetron.

F. Cardenal, X. Garcia-Del-Muro, P. Ferrer, 1993, European journal of cancer.

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.

A. Carrato, E. Felip, R. Rosell, 2003, Lung cancer.

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

A. Carrato, E. Felip, R. Rosell, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive biomarkers in the management of EGFR mutant lung cancer

R. Rosell, M. Taron, S. Benlloch, 2010, Annals of the New York Academy of Sciences.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

R. Rosell, M. Taron, N. Reguart, 2014, Lung cancer.

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Johan Vansteenkiste, J. von Pawel, J. Vansteenkiste, 2009, Investigational New Drugs.

Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer

C. Witt, M. Pajares, L. Montuenga, 2010, Cancer Epidemiology, Biomarkers & Prevention.

sputum from patients with lung cancer

C. Witt, L. Montuenga, R. Pio, 2010 .

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

R. Stahel, R. Rosell, M. Taron, 2011, Lung cancer.

A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.

F. Schramel, E. Quoix, R. Gervais, 2005, Lung cancer.

A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.

G. Scagliotti, W. De Neve, J. V. van Meerbeeck, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer

J. Borrás, J. González-Barboteo, E. Nadal, 2018, British Journal of Cancer.

PET/CT fusion scan in lung cancer: current recommendations and innovations.

R. Rosell, F. Cardenal, C. Gamez, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial.

M. Taron, B. Massuti, C. Camps, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.

R. Rosell, B. Massuti, J. Zamora, 2013, Lung cancer.

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.

E. Nadal, R. Palmero, R. Porta, 2011, Lung cancer.

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

S. Novello, L. Paz-Ares, C. Langer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.

R. Rosell, B. Massuti, P. Garrido, 2009, Clinical lung cancer.